BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37526298)

  • 1. Treatment Persistence and Medication Switch Associated With Subsequent Fractures After Osteoporotic Fractures.
    Lin SY; Chen WJ; Ku CK; Chen YM; Chen CH; Chien LN
    J Clin Endocrinol Metab; 2023 Dec; 109(1):e200-e208. PubMed ID: 37526298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
    Lin SY; Chen YM; Chen WJ; Li CY; Ku CK; Chen CH; Chien LN
    Arch Osteoporos; 2022 Jul; 17(1):94. PubMed ID: 35840845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2022 Jul; 160():116396. PubMed ID: 35351673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
    Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
    J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.
    Wang X; Li C; He Y; Wang T; Zhang H; Ma Z; Ma H; Zhao H
    Arch Osteoporos; 2020 Aug; 15(1):134. PubMed ID: 32820451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A national study on long-term osteoporosis therapy and risk of recurrent fractures in patients with hip fracture.
    Hsu CL; Chen HM; Chen HJ; Chou MY; Wang YC; Hsu YH; Liang CK; Chu CS
    Arch Gerontol Geriatr; 2020; 88():104021. PubMed ID: 32058125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of anti-osteoporosis medications on total hip arthroplasty risks in osteoporotic patients with hip osteoarthritis in Taiwan: a nationwide cohort study.
    Hung CC; Wang CY; Fu SH; Yang RS; Hsiao FY
    Arch Osteoporos; 2018 Oct; 13(1):107. PubMed ID: 30306268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and medicare advantage beneficiaries.
    Malik AT; Retchin S; Phillips FM; Xu W; Peters K; Yu E; Khan SN
    Spine J; 2020 Apr; 20(4):538-546. PubMed ID: 31683068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
    Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: A retrospective study of patients with osteoporosis in a real-world clinical setting.
    Cruchelow KR; Peter ME; Chakrabarti A; Gipson HM; Gregory WT; DeClercq J; Choi L; Tanner SB
    Bone; 2023 Dec; 177():116925. PubMed ID: 37797711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world evaluation of osteoporotic fractures using the Japan Medical Data Vision database.
    Fujiwara S; Buchanan-Hughes A; Ng A; Page J; Adachi K; Li H
    Osteoporos Int; 2022 Oct; 33(10):2205-2216. PubMed ID: 35779100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visualisation of the unmet treatment need of osteoporotic fracture in Taiwan: A nationwide cohort study.
    Wang CY; Fu SH; Huang CC; Hung CC; Yang RS; Hsiao FY
    Int J Clin Pract; 2018 Oct; 72(10):e13246. PubMed ID: 30144247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter.
    Tai TW; Tsai YL; Shih CA; Li CC; Chang YF; Huang CF; Cheng TT; Hwang JS; Lu TH; Wu CH
    J Formos Med Assoc; 2023; 122 Suppl 1():S65-S73. PubMed ID: 37120337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
    Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
    Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
    Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
    Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.